G protein-coupled receptors in cancer

International Journal of Molecular Sciences

Volumn 17, Issue 8, 2016, Pages

  Bar Shavit, Rachel ^a   Maoz, Myriam ^a   Kancharla, Arun ^a   Nag, Jeetendra Kumar ^a   Agranovich, Daniel ^a   Grisaru Granovsky, Sorina ^b   Uziely, Beatrice ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Cancer; CXCR4; G protein coupled receptors (GPCRs); Hippo YAP; LPA(1 6); Oncogenes; PH domain; Protease; Protease activated receptor; Protease activated receptors (PARs); Wnt catenin

Indexed keywords

APC PROTEIN; AXIN; BETA CATENIN; CASEIN KINASE IALPHA; CHEMOKINE RECEPTOR; FRIZZLED PROTEIN; G PROTEIN COUPLED RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; LYSOPHOSPHATIDIC ACID RECEPTOR; PROTEINASE ACTIVATED RECEPTOR; RHO KINASE; TRANSCRIPTION FACTOR YAP1; WNT PROTEIN;

CARCINOGENICITY; DNA METHYLATION; DRUG TARGETING; GENE OVEREXPRESSION; GENE SILENCING; GEP ONCOGENE; GLYCOSYLATION; HIPPO SIGNALING PATHWAY; HUMAN; NEOPLASM; NONHUMAN; ONCOGENE; PALMITOYLATION; PH; POINT MUTATION; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY; ANIMAL; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84982218473     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17081320     Document Type: Review

References (121)

1. Wisler, J.W.; Xiao, K.; Thomsen, A.R.; Lefkowitz, R.J. Recent developments in biased agonism. Curr. Opin. Cell Biol. 2014, 27, 18–24.
2. Kenakin, T. The potential for selective pharmacological therapies through biased receptor signaling. BMC Pharmacol. Toxicol. 2012, 13, 3.
3. Hollenberg, M.D.; Mihara, K.; Polley, D.; Suen, J.Y.; Han, A.; Fairlie, D.P.; Ramachandran, R. Biased signalling and proteinase-activated receptors (PARs): Targeting inflammatory disease. Br. J. Pharmacol. 2014, 171, 1180–1194.
4. Feigin, M.E. Harnessing the genome for characterization of G-protein coupled receptors in cancer pathogenesis. FEBS J. 2013, 280, 4729–4738.
5. Whalen, E.J.; Rajagopal, S.; Lefkowitz, R.J. Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol. Med. 2011, 17, 126–139.
6. Cianfrocca, R.; Tocci, P.; Semprucci, E.; Spinella, F.; di Castro, V.; Bagnato, A.; Rosanò, L. β-Arrestin 1 is required for endothelin-1-induced NF-κB activation in ovarian cancer cells. Life Sci. 2014, 118, 179–184.
7. Rosanò, L.; Cianfrocca, R.; Tocci, P.; Spinella, F.; di Castro, V.; Spadaro, F.; Salvati, E.; Biroccio, A.M.; Natali, P.G.; Bagnato, A. β-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling. Oncogene 2013, 32, 5066–5077.
8. Lappano, R.; Maggiolini, M. G protein-coupled receptors: Novel targets for drugdiscovery in cancer. Nat. Rev. Drug Discov. 2011, 10, 47–60.
9. Dorsam, R.T.; Gutkind, J.S. G-protein-coupled receptors and cancer. Nat. Rev. Cancer. 2007, 7, 79–94.
10. Xu, N.; Bradley, L.; Ambdukar, I.; Gutkind, J.S. A mutant α subunit of G12 potentiates the eicosanoid pathway and is highly oncogenic in NIH 3T3 cells. Proc. Natl. Acad. Sci. USA 1993, 90, 6741–6745.
11. Jiang, H.; Wu, D.; Simon, M.I. The transforming activity of activated G α 12. FEBS Lett. 1993, 330, 319–322.
12. Voyno-Yasenetskaya, T.A.; Pace, A.M.; Bourne, H.R. Mutant α subunits of G12 and G13 proteins induce neoplastic transformation of Rat-1 fibroblasts. Oncogene 1994, 9, 2559–2565.
13. + exchanger by Gα12 class of G proteins. J. Biol. Chem. 1994, 269, 11802–11806.
14. + exchange through distinct Cdc42-dependent and RhoA-dependent pathways. J. Biol. Chem. 1996, 271, 6152–6158.
15. Offermanns, S.; Mancino, V.; Revel, J.P.; Simon, M.I. Vascular system defects and impaired cell chemokinesis as a result of Gα13 deficiency. Science 1997, 275, 533–536.
16. Tigyi, G. Aiming drug discovery at lysophosphatidic acid targets. Br. J. Pharmacol. 2010, 161, 241–247.
17. Contos, J.J.; Ishii, I.; Chun, J. Lysophosphatidic acid receptors. Mol. Pharmacol. 2000, 58, 1188–1196.
18. Willier, S.; Butt, E.; Grunewald, T.G. Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: A focused review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. Biol. Cell 2013, 105, 317–333.
19. Seo, H.; Kim, M.; Choi, Y.; Lee, C.K.; Ka, H. Analysis of lysophosphatidic acid (LPA) receptor and LPA-induced endometrial prostaglandin-endoperoxide synthase 2 expression in the porcine uterus. Endocrinology 2008, 149, 6166–6167.
20. Wang, P.; Wu, X.; Chen, W.; Liu, J.; Wang, X. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms. Gynecol. Oncol. 2007, 104, 714–720.
21. Rosanò, L.; Spinella, F.; Bagnato, A. Endothelin 1 in cancer: Biological implications and therapeutic opportunities. Nat. Rev. Cancer. 2013, 13, 637–651.
22. Venkatakrishnan, A.J.; Deupi, X.; Lebon, G.; Tate, C.G.; Schertler, G.F.; Babu, M.M. Molecular signatures of G-protein-coupled receptors. Nature 2013, 494, 185–194.
23. Bodor, E.T.; Offermanns, S. Nicotinic acid: An old drug with a promising future. Br. J. Pharmacol. 2008, 153, S68–S75.
24. Soto, A.G.; Smith, T.H.; Chen, B.; Bhattacharya, S.; Cordova, I.C.; Kenakin, T.; Vaidehi, N.; Trejo, J. N-linked glycosylation of protease-activated receptor-1 at extracellular loop 2 regulates G-protein signaling bias. Proc. Natl. Acad. Sci. USA 2015, 112, E3600–E3608.
25. Kenakin, T. Functional selectivity and biased receptor signaling. J. Pharmacol. Exp. Ther. 2011, 336, 296–302.
26. Gesty-Palmer, D.; Chen, M.; Reiter, E.; Ahn, S.; Nelson, C.D.; Wang, S.; Eckhardt, A.E.; Cowan, C.L.; Spurney, R.F.; Luttrell, L.M.; et al. Distinct β-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J. Biol. Chem. 2006, 281, 10856–10864.
27. Bryja, V.; Gradl, D.; Schambony, A.; Arenas, E.; Schulte, G. B-arrestin is a necessary component of Wnt/β-catenin signaling in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2007, 104, 6690–6695.
28. Rosanò, L.; Cianfrocca, R.; Masi, S.; Spinella, F.; di Castro, V.; Biroccio, A.; Salvati, E.; Nicotra, M.R.; Natali, P.G.; Bagnato, A. B-arrestin links endothelin A receptor to β-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc. Natl. Acad. Sci. USA 2009, 106, 2806–2811.
29. Young, D.; Waitches, G.; Birchmeier, C.; Fasano, O.; Wigler, M. Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell 1986, 45, 711–719.
30. Davenport, A.P.; Alexander, S.P.; Sharman, J.L.; Pawson, A.J.; Benson, H.E.; Monaghan, A.E.; Liew, W.C.; Mpamhanga, C.P.; Bonner, T.I.; Neubig, R.R.; et al. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: Recommendations for new pairings with cognate ligands. Pharmacol. Rev. 2013, 65, 967–986.
31. Zohn, I.E.; Klinger, M.; Karp, X.; Kirk, H.; Symons, M.; Chrzanowska-Wodnicka, M.; Der, C.J.; Kay, R.J. G2A is an oncogenic G protein-coupled receptor. Oncogene 2000, 19, 3866–3877.
32. Weng, Z.; Fluckiger, A.C.; Nisitani, S.; Wahl, M.I.; Le, L.Q.; Hunter, C.A.; Fernal, A.A.; Le Beau, M.M.; Witte, O.N. A DNA damage and stress inducible G protein-coupled receptor blocks cells in G2/M. Proc. Natl. Acad. Sci. USA 1998, 95, 12334–12339.
33. Martin, C.B.; Mahon, G.M.; Klinger, M.B.; Kay, R.J.; Symons, M.; Der, C.J.; Whitehead, I.P. The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways. Oncogene 2001, 20, 1953–1963.
34. Whitehead, I.; Kirk, H.; Kay, R. Expression cloning of oncogenes by retroviral transfer of cDNA libraries. Mol. Cell. Biol. 1995, 15, 704–710.
35. Even-Ram, S.; Uziely, B.; Cohen, P.; Grisaru-Granovsky, S.; Maoz, M.; Ginzburg, Y.; Reich, R.; Vlodavsky, I.; Bar-Shavit, R. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat. Med. 1998, 4, 909–914.
36. Xu, N.; Voyno-Yasenetskaya, T.; Gutkind, J.S. Potent transforming activity of the G13α subunit defines a novel family of oncogenes. Biochem. Biophys. Res. Commun. 1994, 201, 603–609.
37. Kawanabe, Y.; Okamoto, Y.; Nozaki, K.; Hashimoto, N.; Miwa, S.; Masaki, T. Molecular mechanism for endothelin-1-induced stress-fiber formation: Analysis of G proteins using a mutant endothelin(A) receptor. Mol. Pharmacol. 2002, 61, 277–284.
38. Kelly, P.; Casey, P.J.; Meigs, E. Biologic functions of the G12 subfamily of heterotrimeric G proteins: Growth, migration, and metastasis. Biochemistry 2007, 46, 6677–6687.
39. Lee, S.J.; Yang, J.W.; Cho, I.J.; Kim, W.D.; Cho, M.K.; Lee, C.H.; Kim, S.G. The Gep oncogenes, Gα and Gα, upregulate the transforming growth factor-β1 gene. Oncogene 2009, 28, 1230–1240.
40. Simon, M.I.; Strathmann, M.P.; Gautam, N. Diversity of G proteins in signal transduction. Science 1991, 252, 802–808.
41. Hepler, J.R.; Gilman, A.G. G proteins. Trends Biochem. Sci. 1992, 17, 383–395.
42. Conklin, B.R.; Bourne, H.R. Structural elements of G α subunits that interact with Gβγ, receptors, and effectors. Cell 1993, 73, 631–641.
43. Chan, A.M.; Fleming, T.P.; McGovern, E.S.; Chedid, M.; Miki, T.; Aaronson, S.A. Expression cDNA cloning of a transforming gene encoding the wild-type Gα12 gene product. Mol. Cell. Biol. 1993, 13, 762–768.
44. Dhanasekaran, N.; Dermott, J.M. Signaling by the G12 class of G proteins. Cell Signal. 1996, 8, 235–245.
45. Goldsmith, Z.G.; Dhanasekaran, D.N. G protein regulation of MAPK networks. Oncogene 2007, 26, 3122–3142.
46. Kuner, R.; Swiercz, J.M.; Zywietz, A.; Tappe, A.; Offermanns, S. Characterization of the expression of PDZ-RhoGEF, LARG and G(α)12/G(α)13 proteins in the murine nervous system. Eur. J. Neurosci. 2002, 16, 2333–2340.
47. Kurose, H. Gα12 and Gα13 as key regulatory mediator in signal transduction. Life Sci. 2003, 74, 155–161.
48. Fujii, T.; Onohara, N.; Maruyama, Y.; Tanabe, S.; Kobayashi, H.; Fukutomi, M.; Nagamatsu, Y.; Nishihara, N.; Inoue, R.; Sumimoto, H.; et al. Gα12/13-mediated production of reactive oxygen species is critical for angiotensin receptor-induced NFAT activation in cardiac fibroblasts. J. Biol. Chem. 2005, 280, 23041–23047.
49. Kumar, R.N.; Shore, S.K.; Dhanasekaran, N. Neoplastic transformation by the Gep oncogene, Gα12, involves signaling by STAT3. Oncogene 2006, 25, 899–906.
50. Noguchi, K.; Ishii, S.; Shimizu, T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J. Biol. Chem. 2003, 278, 25600–25606.
51. Lee, C.W.; Rivera, R.; Gardell, S.; Dubin, A.E.; Chun, J. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J. Biol. Chem. 2006, 281, 23589–23597.
52. Tabata, K.; Baba, K.; Shiraishi, A.; Ito, M.; Fujita, N. The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem. Biophys. Res. Commun. 2007, 363, 861–866.
53. Mills, G.B.; Moolenaar, W.H. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer 2003, 3, 582–591.
54. Yang, M.; Zhong, W.W.; Srivastava, N.; Slavin, A.; Yang, J.; Hoey, T.; An, S. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the β-catenin pathway. Proc. Natl. Acad. Sci. USA 2005, 102, 6027–6032.
55. Chen, M.; Towers, L.N.; O’Connor, K.L. LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells. Am. J. Physiol. Cell Physiol. 2007, 292, C1927–C1933.
56. Bian, D.; Mahanivong, C.; Yu, J.; Frisch, S.M.; Pan, Z.K.; Ye, R.D.; Huang, S. The G12/13-Rho a signaling pathway contributes to efficient lysophosphatidic acid-stimulated cell migration. Oncogene 2006, 25, 2234–2244.
57. Aoki, J.; Taira, A.; Takanezawa, Y.; Kishi, Y.; Hama, K.; Kishimoto, T.; Mizuno, K.; Saku, K.; Taguchi, R.; Arai, H. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J. Biol. Chem. 2002, 277, 48737–48744.
58. Balkwill, F. Cancer and the chemokine network. Nat. Rev. Cancer 2004, 4, 540–550.
59. Zlotnik, A.; Burkhardt, A.M.; Homey, B. Homeostatic chemokine receptors and organ-specific metastasis. Nat. Rev. Immunol. 2011, 11, 597–606.
60. O’Hayre, M.; Salanga, C.L.; Handel, T.M.; Allen, S.J. Chemokines and cancer: Migration, intracellular signalling and intercellular communication in the microenvironment. Biochem. J. 2008, 409, 635–649.
61. Müller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M.E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S.N.; et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410, 50–56.
62. Chambers, A.F.; Groom, A.C.; MacDonald, I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2, 563–572.
63. Burger, J.A.; Kipps, T.J. CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107, 1761–1767.
64. Staller, P.; Sulitkova, J.; Lisztwan, J.; Moch, H.; Oakeley, E.J.; Krek, W. Chemokine receptor CXCR4 down regulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003, 425, 307–311.
65. Yagi, H.; Tan, W.; Dillenburg-Pilla, P.; Armando, S.; Amornphimoltham, P.; Simaan, M.; Weigert, R.; Molinolo, A.A.; Bouvier, M.; Gutkind, J.S. A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. Sci. Signal. 2011, 4, ra60.
66. Clevers, H. Wnt/β-catenin signaling in development and disease. Cell 2006, 127, 469–480.
67. Nusse, R. Wnt signaling in disease and in development. Cell Res. 2005, 15, 28–32.
68. −/− colon carcinoma. Science 1997, 275, 1784–1787.
69. Valenta, T.; Hausmann, G.; Basler, K. The many faces and functions of β-catenin. EMBO J. 2012, 31, 2714–2736.
70. Van Amerongen, R. Alternative Wnt pathways and receptors. Cold Spring Harb. Perspect. Biol. 2012, 4, a007914.
71. Katanaev, V.L.; Ponzielli, R.; Sémériva, M.; Tomlinson, A. Trimeric G protein-dependent frizzled signaling in Drosophila. Cell 2005, 120, 111–122.
72. Liu, T.; DeCostanzo, A.J.; Liu, X.; Wang, Hy.; Hallagan, S.; Moon, R.T.; Malbon, C.C. G protein signaling from activated rat frizzled-1 to the β catenin-Lef-Tcf pathway. Science 2001, 292, 1718–1722.
73. Slusarski, D.C.; Corces, V.G.; Moon, R.T. Interaction of Wnt and a Frizzled homologue triggers G-protein-linked phosphatidylinositol signalling. Nature 1997, 390, 410–413.
74. Major, M.B.; Roberts, B.S.; Berndt, J.D.; Marine, S.; Anastas, J.; Chung, N.; Ferrer, M.; Yi, X.; Stoick-Cooper, C.L.; von Haller, P.D.; et al. New regulators of Wnt/β-catenin signaling revealed by integrative molecular screening. Sci. Signal. 2008, 1, ra12.
75. Regard, J.B.; Cherman, N.; Palmer, D.; Kuznetsov, S.A.; Celi, F.S.; Guettier, J.M.; Chen, M.; Bhattacharyya, N.; Wess, J.; Coughlin, S.R.; et al. Wnt/B-catenin signaling is differentially regulated by Ga proteins and contributes to fibrous dysplasia. Proc. Natl. Acad. Sci. USA 2011, 108, 20101–20106.
76. Miller, E.; Yang, J.; DeRan, M.; Wu, C.; Su, A.I.; Bonamy, G.M.; Liu, J.; Peters, E.C.; Wu, X. Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP. Chem. Biol. 2012, 19, 955–962.
77. Mo, J.S.; Yu, F.X.; Gong, R.; Brown, J.H.; and Guan, K.L. Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). Genes Dev. 2012, 26, 2138–2143.
78. Yu, F.X.; Zhao, B.; Panupinthu, N.; Jewell, J.L.; Lian, I.; Wang, L.H.; Zhao, J.; Yuan, H.; Tumaneng, K.; Li, H.; et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012, 150, 780–791.
79. Yu, F.X.; Luo, J.; Mo, J.S.; Liu, G.; Kim, Y.C.; Meng, Z.; Zhao, L.; Peyman, G.; Ouyang, H.; Jiang, W.; et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 2014, 25, 822–830.
80. Pan, D. The hippo signaling pathway in development and cancer. Dev. Cell 2010, 19, 491–505.
81. Yu, F.X.; Zhang, Y.; Park, H.W.; Jewell, J.L.; Chen, Q.; Deng, Y.; Pan, D.; Taylor, S.S.; Lai, Z.C.; Guan, K.L. Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. Genes Dev. 2013, 27, 1223–1232.
82. Ramos, A.; Camargo, F.D. The Hippo signaling pathway and stem cell biology. Trends Cell Biol. 2012, 22, 339–346.
83. Zhao, B.; Li, L.; Lei, Q.; Guan, K.L. The Hippo-YAP pathway in organ size control and tumorigenesis: An updated version. Genes Dev. 2010, 24, 862–874.
84. Sudol, M.; Bork, P.; Einbond, A.; Kastury, K.; Druck, T.; Negrini, M.; Huebner, K.; Lehman, D. Characterization of the mammalian YAP (Yes-associated protein) gene and its role in defining a novel protein module, the WW domain. J. Biol. Chem. 1995, 270, 14733–14741.
85. Feng, X.; Degese, M.S.; Iglesias-Bartolome, R.; Vaque, J.P.; Molinolo, A.A.; Rodrigues, M.; Zaidi, M.R.; Ksander, B.R.; Merlino, G.; Sodhi, A.; et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell 2014, 25, 831–845.
86. Park, H.W.; Kim, Y.C.; Yu, B.; Moroishi, T.; Mo, J.S.; Plouffe, S.W.; Meng, Z.; Lin, K.C.; Yu, F.X.; Alexander, C.M.; et al. Alternative Wnt signaling activates YAP/TAZ. Cell 2015, 162, 780–789.
87. Rosenbluh, J.; Nijhawan, D.; Cox, G.; Li, X.; Neal, J.T.; Schafer, E.J.; Zack, T.I.; Wang, X.; Tsherniak, A.; Schinzel, A.C.; et al. β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 2012, 151, 1457–1473.
88. Puente, X.S.; Gutiérrez-Fernández, A.; Ordóñez, G.R.; Hillier, L.W.; López-Otín, C. Comparative genomic analysis of human and chimpanzee proteases. Genomics 2005, 86, 638–647.
89. Burger, M.M. Proteolytic enzymes initiating cell division and escape from contact inhibition of growth. Nature 1970, 227, 170–171.
90. Chen, L.B.; Buchanan, J.M. Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc. Natl. Acad. Sci. USA 1975, 72, 131–135.
91. Carney, D.H.; Cunningham, D.D. Initiation of check cell division by trypsin action at the cell surface. Nature 1977, 268, 602–606.
92. Carney, D.H.; Cunningham, D.D. Cell surface action of thrombin is sufficient to initiate division of chick cells. Cell 1978, 14, 811–823.
93. 2+ mobilization. FEBS Lett. 1991, 288, 123–128.
94. Vu, T.K.; Hung, D.T.; Wheaton, V.I.; Coughlin, S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991, 64, 1057–1068.
95. Coughlin, S.R. Protease-activated receptors start a family. Proc. Natl. Acad. Sci. USA 1994, 91, 9200–9202.
96. Ishihara, H.; Connolly, A.J.; Zeng, D.; Kahn, M.L.; Zheng, Y.W.; Timmons, C.; Tram, T.; Coughlin, S.R. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997, 386, 502–506.
97. Kahn, M.L.; Zheng, Y.W.; Huang, W.; Bigornia, V.; Zeng, D.; Moff, S.; Farese, R.V.J.; Tam, C.; Coughlin, S.R. A dual thrombin receptor system for platelet activation. Nature 1998, 394, 690–694.
98. Xu, W.F.; Andersen, H.; Whitmore, T.E.; Presnell, S.R.; Yee, D.P.; Ching, A.; Gilbert, T.; Davie, E.W.; Foster, D.C. Cloning and characterization of human protease-activated receptor 4. Proc. Natl. Acad. Sci. USA 1998, 95, 6642–6646.
99. Nystedt, S.; Emilsson, K.; Wahlestedt, C.; Sundelin, J. Molecular cloning of a potential proteinase activated receptor. Proc. Natl. Acad. Sci. USA 1994, 91, 9208–9210.
100. Coughlin, S.R. How the protease thrombin talks to cells. Proc. Natl. Acad. Sci. USA 1999, 96, 11023–11027.
101. Oldham, W.M.; Hamm, H.E. Heterotrimeric G protein activation by G-protein-coupled receptors. Nat. Rev. Mol. Cell Biol. 2008, 9, 60–71.
102. 1&2 endow breast cancer growth. Nat. Commun. 2015, 6, 8853–8865.
103. Konishi, H.; Kuroda, S.; Kikkawa, U. The pleckstrin homology domain of RAC protein kinase associates with the regulatory domain of protein kinase C zeta. Biochem. Biophys. Res. Commun. 1994, 205, 1770–1775.
104. Yao, L.; Kawakami, Y.; Kawakami, T. The pleckstrin homology domain of Bruton tyrosine kinase interacts with protein kinase C. Proc. Natl. Acad. Sci. USA 1994, 91, 9175–9179.
105. Even-Ram, S.C.; Maoz, M.; Pokroy, E.; Reich, R.; Katz, B.Z.; Gutwein, P.; Altevogt, P.; Bar-Shavit, R. Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the α vβ 5 integrin. J. Biol. Chem. 2001, 276, 10952–10962.
106. Jeong, K.J.; Park, S.Y.; Cho, K.H.; Sohn, J.S.; Lee, J.; Kim, Y.K.; Kang, J.; Park, C.G.; Han, J.W.; Lee, H.Y. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion. Oncogene 2012, 31, 4279–4289.
107. Sun, Y.; Kim, N.H.; Ji, L.; Kim, S.H.; Lee, J.; Rhee, H.J. Lysophosphatidic acid activates β-catenin/T cell factor signaling, which contributes to the suppression of apoptosis in H19–7 cells. Mol. Med. Rep. 2013, 8, 1729–1733.
108. Burkhalter, R.J.; Westfall, S.D.; Liu, Y.; Stack, M.S. Lysophosphatidic acid initiates epithelial to mesenchymal transition and induces β-catenin-mediated transcription in epithelial ovarian carcinoma. J. Biol. Chem. 2015, 290, 22143–22154.
109. Zhang, H.; Bialkowska, A.; Rusovici, R.; Chanchevalap, S.; Shim, H.; Katz, J.P.; Yang, V.W.; Yun, C.C. Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Krüppel-like factor 5. J. Biol. Chem. 2007, 282, 15541–15549.
110. Moroishi, T.; Park, H.W.; Qin, B.; Chen, Q.; Meng, Z.; Plouffe, S.W.; Taniguchi, K.; Yu, F.X.; Karin, M.; Pan, D.; et al. A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis. Genes Dev. 2015, 29, 1271–1284.
111. Yin, Y.J.; Katz, V.; Salah, Z.; Maoz, M.; Cohen, I.; Uziely, B.; Turm, H.; Grisaru-Granovsky, S.; Suzuki, H.; Bar-Shavit, R. Mammary gland tissue targeted overexpression of human protease-activated receptor 1 reveals a novel link to β-catenin stabilization. Cancer Res. 2006, 66, 5224–5233.
112. Turm, H.; Maoz, M.; Katz, V.; Yin, Y.J.; Offermanns, S.; Bar-Shavit, R. Protease-activated receptor-1 (PAR1) acts via a novel Gα13-dishevelled axis to stabilize β-catenin levels. J. Biol. Chem. 2010, 285, 15137–15148.
113. Romero, G.; Sneddon, W.B.; Yang, Y.; Wheeler, D.; Blair, H.C.; Friedman, P.A. Parathyroid hormone receptor directly interacts with dishevelled to regulate β-Catenin signaling and osteoclastogenesis. J. Biol. Chem. 2010, 285, 14756–14763.
114. Malbon, C.C. Frizzleds: New members of the superfamily of G-protein-coupled receptors. Front. Biosci. 2004, 9, 1048–1058.
115. Cojoc, M.; Peitzsch, C.; Trautmann, F.; Polishchuk, L.; Telegeev, G.D.; Dubrovska, A. Emerging targets in cancer management: Role of the CXCL12/CXCR4 axis. Onco. Targets Ther. 2013, 6, 1347–1361.
116. Rosanò, L.; Bagnato, A. Endothelin therapeutics in cancer: Where are we? Am. J. Physiol. Regul. Integr. Comp. Physiol. 2016, 310, R469–R475.
117. Dannenberg, A.J.; Subbaramaiah, K. Targeting cyclooxygenase-2 in human neoplasia: Rationale and promise. Cancer Cell 2003, 4, 431–436.
118. Hull, M.A.; Ko, S.C.; Hawcroft, G. Prostaglandin EP receptors: Targets for treatment and prevention of colorectal cancer? Mol. Cancer Ther. 2004, 3, 1031–1039.
119. O’Callaghan, G.; Houston, A. Prostaglandin E2 and the EP receptors in malignancy: Possible therapeutic targets? Br. J. Pharmacol. 2015, 172, 5239–5250.
120. Taub, J.S.; Guo, R.L.; Leeb-Lundberg, M.F.; Madden, J.F.; Daaka, Y. Bradykinin receptor subtype 1 expression and function in prostate cancer. Cancer Res. 2003, 63, 2037–2041.
121. Liu, Y.; An, S.; Ward, R.; Yang, Y.; Guo, X.X.; Li, W.; Xu, T.R. G protein-coupled receptors as promising cancer targets. Cancer Lett. 2016, 376, 226–239.